Digest Réseau Comment ça marche
Réseau
/
Sociétés
Bi
Non vérifié

Biogen Inc.

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieFinanceManagement/Organisation d'EntrepriseMédecine Santé Bien-être

51 communiqués de presse

Voir tous les communiqués de presse
05/12/2025
Biotechnologie
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
24/11/2025
Biotechnologie
Médecine Santé Bien-être
Management/Organisation d'Entreprise
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotechnologie
Médecine Santé Bien-être
Annonces Économiques
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotechnologie
Médecine Santé Bien-être
Annonces Économiques
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
14/11/2025
Biotechnologie
Médecine Santé Bien-être
Annonces Économiques
Biogen Completes Acquisition of Alcyone Therapeutics
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
03/11/2025
Biotechnologie
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
24/10/2025
Biotechnologie
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
22/10/2025
Biotechnologie
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
13/10/2025
Biotechnologie
Annonces Économiques
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
09/10/2025
Biotechnologie
Médecine Santé Bien-être
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0